Abstract: Objective：To determine the effect of PTK787 on the expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 mRNA, and further discuss the role of PTK787 on anti-acute myeloid leukemia. Methods：The acute myeloid leukemia model was established on 40 severe combined immunodeficiency mice by HL-60 cells transplantation.The mice were divided into five group randomly,the normal group, the sicken group，the treated group with 50mg/kg PTK787, the treated group with 100mg/kg PTK787, the treated group with 200mg/kg PTK787. Logarithmic phase cells were implanted into the sicken group and the treated group by celiac injection. The expression of vascular endothelial growth factor was detected by enzyme linked immunosorbent assay. The expression of vascular endothelial growth factor receptor-2 mRNA was detected by reverse transcription-polymerase chain reaction. Results：(1) Expression of vascular endothelial growth factors and vascular endothelial growth factor receptor-2 mRNA were determined on all mice.(2)Compared with the normal group, the mRNA level of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in the sicken group was significantly and gradually increased with the course of disease. （3）Compared with the sicken group, the expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 mRNA of treated group decreased obviously. Conclusion：The anti-effect on acute myeloid leukemia of PTK787 is related with the decrease expression of vascular endothelial growth factor and vascular endothelial growth factor receptor -2.